Evidence map›Paper›PMID 39575409›Full record

SynthesisWorld journal of gastroenterology2024

Prevalence of

Lu Xie, Guang-Wei Liu, Ya-Nan Liu, Peng-Yu Li, Xin-Ning Hu, Xin-Yi He, Rui-Bo Huan, Tai-Long Zhao, Hui-Jun Guo

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Meta-analysis ofFrontiers in cellular and infection microbiology · 2025
    Pooled it
  2. Trial
  3. Efficacy and safety of triple therapy with vonoprazan forWorld journal of gastroenterology · 2025
    Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. From screening to surveillance: integrated prevention ofThe Lancet regional health. Western Pacific · 2026
    Review
  9. Current status ofFujita medical journal · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Efficacy and Safety of Tegoprazan inPharmaceuticals (Basel, Switzerland) · 2026
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. The association of the advanced lung cancer inflammation index with the risk ofFrontiers in cellular and infection microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lu XieDepartment of Acquired Immune Deficiency Syndrome Treatment and Research Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China.
Guang-Wei LiuDepartment of Spleen, Stomach, Liver and Gallbladder, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China.
Ya-Nan LiuDepartment of Acquired Immune Deficiency Syndrome Treatment and Research Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China.
Peng-Yu LiDepartment of Acquired Immune Deficiency Syndrome Treatment and Research Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China.
Xin-Ning HuDepartment of Acquired Immune Deficiency Syndrome Treatment and Research Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China.
Xin-Yi HeDepartment of Acquired Immune Deficiency Syndrome Treatment and Research Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China.
Rui-Bo HuanDepartment of Acquired Immune Deficiency Syndrome Treatment and Research Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China.
Tai-Long ZhaoDepartment of Acquired Immune Deficiency Syndrome Treatment and Research Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China.
Hui-Jun GuoDepartment of Acquired Immune Deficiency Syndrome Treatment and Research Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

aimTo methodically evaluate the occurrence of

methodsA systematic review and meta-analysis was conducted following established guidelines, as detailed in our methodology section.

resultsOur review synthesized data from 152 studies, covering a sample of 763827 individuals, 314423 of whom were infected with

conclusionBetween 2014 and 2023, the prevalence of

Indexed as

Helicobacter InfectionsHelicobacter pyloriAdultAgedChildChinaFemaleHumansMaleMiddle AgedPrevalenceStomach NeoplasmsYoung AdultChinaEpidemiologyHelicobacter pyloriMeta-analysisPrevalence

Identifiers

PMID39575409
PMCPMC11572641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.